The event, part of the #CheckYourFoodTube campaign, was held in Cincinnati, Ohio.
Stock.adobe.com
Lucid Diagnostics launched its first-ever #CheckYourFoodTube Precancer Testing Event in Cincinnati, Ohio.1 The campaign is focused on educating the connection between gastroesphageal reflux disease and esophageal cancer. The disease is more commonly known as chronic heartburn,
The campaign is targeted at former NFL players. The first event featured an educational section, which was followed by on-site testing for the former players.
In a press release, former Cincinnati Bengals player and team leader of the Sports-Health Alliance at Russo Partners Solomon Wilcots said, “Collaborating with Lucid Diagnostics on this inaugural event is just the beginning of what we hope will be a game-changing initiative for former NFL players across the country. As athletes who've put our bodies on the line throughout our careers, we have a heightened awareness of the importance of protecting our long-term health. EsoGuard offers us a crucial opportunity for early detection of esophageal precancer, which can truly be a lifesaver. I strongly encourage all my peers in the sports community to take proactive steps in safeguarding their health from this deadly, yet preventable cancer. Remember, when it comes to esophageal cancer, early detection is the best—it's time we all 'Check Our Food Tubes!'"
Lucid chairman and CEO Lishan Aklog added, “These educational and precancer testing events targeting former NFL players provide us with a great opportunity to increase awareness of highly lethal but now preventable esophageal cancer. Individuals with heartburn and other risk factors (age over 50, male, white race, obesity, smoking, or a family history), whether former NFL players or their legions of fans, can now undergo a quick and simple test to determine whether they may have precancer and take appropriate steps to prevent this cancer. We are committed to getting the word out and appreciate Mr. Wilcots and his compatriots using their platform to help us do so."
Lucid also recently signed a memorandum of understanding with Front Line Mobile Health.2 This partnership will result in co-marketing initiatives targeted at firefighters.
In a press release issued in early September, Lucid president and chief operating officer Shaun O’Neil said, “Lucid Diagnostics is committed to widespread early detection of esophageal precancer. We are honored to have provided EsoGuard precancer testing to thousands of firefighters across the nation. Every day they risk their lives to protect us, and Lucid is committed to protecting them in return. This partnership allows us to expand these efforts by leveraging Front Line's resources and extensive expertise caring for firefighters. We are excited to further collaborate with Front Line to increase access to esophageal precancer testing for firefighters and drive revenue through contracted high-volume testing events."
In the same press release, Front Line team principal and CEO Russell A. Burnham added, “At Front Line Mobile Health, we are deeply committed to protecting the health and safety of our nation's firefighters, who face a 62% higher risk of developing esophageal cancer. Lucid's EsoGuard Esophageal DNA Test is a powerful tool in this endeavor, offering early detection of esophageal precancer and thereby safeguarding the well-being of these brave individuals. We look forward to expanding our partnership with Lucid and leveraging our strong relationships with fire departments to broaden access to this potentially life-saving tool."
Asembia 2025: Therapy Advancements Highlight Growing Cost and Access Concerns
April 30th 2025Fran Gregory, VP, emerging therapies, Cardinal Health, discusses the evolving cell and gene therapy landscape, highlighting pipeline growth, cost challenges, and emerging therapeutic areas beyond oncology and hematology.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
FDA Approves AbbVie’s Rinvoq as First Oral JAK Inhibitor for Giant Cell Arteritis
April 30th 2025AbbVie secures FDA approval for Rinvoq as the first oral Janus kinase inhibitor indicated for giant cell arteritis, expanding its immunology portfolio and signaling strategic growth opportunities in underserved autoimmune markets.